CelLBxHealth plc (LSE:CLBX) has announced that its Parsortix platform featured in an independent, peer-reviewed study demonstrating the technology’s ability to identify key antibody-drug conjugate (ADC) biomarkers on circulating tumour cells (CTCs) from patients with triple-negative breast cancer and epithelial ovarian cancer. The findings add to the growing body of evidence supporting the platform’s application in precision oncology and treatment monitoring.
Study Demonstrates Detection of Key Cancer Biomarkers
The research, carried out by investigators in Dublin and published in The Journal of Liquid Biopsy, showed that the Parsortix system successfully detected clinically relevant biomarkers including TROP-2, FRα and PD-L1 on circulating tumour cells. Importantly, the platform was able to identify these targets even on tumour cells with low EpCAM expression, highlighting its ability to capture a broader and more diverse population of CTCs than conventional approaches.
The results reinforce the technology’s potential value in monitoring the biological changes that occur during cancer treatment.
Opportunity in the Expanding ADC Market
CelLBxHealth believes the study supports the use of Parsortix as a minimally invasive tool for real-time biomarker assessment within the fast-growing antibody-drug conjugate market, where changes in target expression can influence treatment selection and effectiveness.
Management said the findings are consistent with the company’s strategy of focusing on high-value applications for circulating tumour cell analysis across research, pharmaceutical development and translational oncology. The additional clinical evidence could help strengthen relationships with drug developers and healthcare professionals seeking more advanced methods of monitoring patient response to therapy.
Financial Challenges Continue to Temper Outlook
Despite the positive scientific validation, CelLBxHealth continues to face significant financial headwinds. Weak financial performance and negative technical indicators remain the primary factors affecting the company’s overall outlook.
While recent corporate developments and progress highlighted during earnings updates provide some encouragement, concerns surrounding profitability and valuation continue to weigh on investor sentiment.
About CelLBxHealth plc
CelLBxHealth plc is a biotechnology company specialising in circulating tumour cell intelligence for cancer research, drug development and clinical oncology. Its patented Parsortix platform isolates circulating tumour cells from blood samples for downstream imaging, genomic and proteomic analysis, supporting the development of personalised cancer treatments.
The company generates revenue through sales of Parsortix instruments and consumables, laboratory services for clinical studies, assay development and the expansion of laboratory-developed testing programmes through both partnerships and internal initiatives.
Leave a Reply